A 38-year-old woman with a history of recurrent acute pancreatitis is admitted with severe epigastric pain, nausea, and vomiting. Laboratory investigations show: serum amylase 950 U/L, lipase 1800 U/L, serum calcium 7.2 mg/dL (normal 8.5–10.5), albumin 3.1 g/dL, and AST 180 U/L. Abdominal CT shows pancreatic edema without necrosis. Gallbladder ultrasound is normal. Genetic testing for CFTR mutations is positive. What is the most appropriate next step in management after initial supportive care?

Explanation

## Diagnosis: Cystic Fibrosis–Related Pancreatitis with Pancreatic Insufficiency ### Clinical Context This patient presents with: - **Recurrent acute pancreatitis** (history of recurrent episodes) - **Positive CFTR mutation** (cystic fibrosis) - **Hypocalcemia (7.2 mg/dL)** — suggests fat malabsorption and vitamin D deficiency - **Hypoalbuminemia (3.1 g/dL)** — indicates nutritional compromise - **Normal gallbladder** — excludes biliary etiology ### Why Pancreatic Enzyme Supplementation is Correct **Key Point:** Cystic fibrosis (CF) causes progressive pancreatic damage, leading to both acute pancreatitis AND chronic pancreatic insufficiency. The hypocalcemia and hypoalbuminemia in this patient signal **exocrine pancreatic insufficiency** (EPI). **High-Yield:** In CF-related pancreatitis: 1. **Acute phase:** NPO, IV fluids, analgesia (standard supportive care) 2. **Chronic management:** Pancreatic enzyme replacement therapy (PERT) + fat-soluble vitamin supplementation (A, D, E, K) The hypocalcemia reflects vitamin D malabsorption due to fat malabsorption — this is corrected by: - **Pancreatic enzyme supplementation** (lipase-containing formulations) to restore fat digestion - **Fat-soluble vitamin replacement** (especially vitamin D and calcium supplementation) ### Pathophysiology of CF Pancreatitis ```mermaid flowchart TD A[CFTR gene mutation]:::outcome --> B[Defective CFTR protein in pancreatic ducts]:::outcome B --> C[Thick, viscous pancreatic secretions]:::outcome C --> D[Ductal obstruction & protein plug formation]:::outcome D --> E[Recurrent acute pancreatitis]:::urgent E --> F[Progressive acinar atrophy]:::outcome F --> G[Exocrine pancreatic insufficiency]:::outcome G --> H[Fat malabsorption]:::outcome H --> I[Fat-soluble vitamin deficiency]:::outcome I --> J[Hypocalcemia, hypoproteinemia]:::outcome J --> K[PERT + vitamin replacement]:::action ``` ### Management of CF-Related Pancreatitis | Phase | Intervention | Rationale | |-------|--------------|----------| | **Acute** | NPO, IV fluids, analgesia, oxygen | Standard supportive care | | **Chronic** | Pancreatic enzyme replacement (PERT) | Restore fat/protein digestion | | **Chronic** | Fat-soluble vitamins (A, D, E, K) | Correct malabsorption-related deficiencies | | **Chronic** | Nutritional counseling, high-calorie diet | Maintain nutritional status | | **Chronic** | Ursodeoxycholic acid (if biliary involvement) | Protect biliary epithelium | **Clinical Pearl:** Hypocalcemia in pancreatitis has two mechanisms: 1. **Acute pancreatitis:** Saponification of fat (acute phase) → transient hypocalcemia 2. **CF-related pancreatitis:** Chronic fat malabsorption → vitamin D deficiency → persistent hypocalcemia This patient's hypocalcemia is likely **chronic** (from EPI), not acute saponification, making vitamin D replacement essential. ### Why Other Options Are Wrong **ERCP** is not indicated because: - No evidence of biliary obstruction or ductal stricture - Therapeutic ERCP is reserved for CF patients with symptomatic ductal obstruction or recurrent pancreatitis unresponsive to medical therapy - This patient is in the acute phase and requires initial supportive care + chronic PERT **Azathioprine** is used for autoimmune pancreatitis, not CF-related pancreatitis. **Whipple procedure** (pancreaticoduodenectomy) is a last-resort intervention for intractable pain in chronic pancreatitis, not indicated in acute pancreatitis or as first-line management.